Literature DB >> 14704805

Colonic anastomotic disruption in the immediate postoperative period.

G R Hirst1, S S Karandikar, G Brown, H Slowey, J Beynon.   

Abstract

BACKGROUND: Muscle relaxation is administered to patients undergoing laparotomy for colonic surgery. At the end of the procedure, relaxation needs to be reversed to facilitate extubation. This may be achieved by administering anticholinesterases such as neostigmine. PATIENT
PRESENTATION: We present a case of colonic anastomotic dehiscence in the immediate postoperative period following the use of neostigmine to reverse intra-operative muscle relaxation.
CONCLUSION: Neostigmine is frequently used to reverse muscle relaxation at the end of colonic surgery. However, the drug should be used with caution as it has been implicated as a cause of early anastomotic disruption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14704805     DOI: 10.1007/s00384-003-0564-2

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  4 in total

1.  Neostigmine increases postoperative colonic motility in patients undergoing colorectal surgery.

Authors:  M E Kreis; M Kasparek; T T Zittel; H D Becker; E C Jehle
Journal:  Surgery       Date:  2001-09       Impact factor: 3.982

2.  Does neostigmine have a deleterious effect on the resistance of colonic anastomoses?

Authors:  D C García-Olmo; M García-Rivas; D García-Olmo
Journal:  Eur J Anaesthesiol       Date:  1998-01       Impact factor: 4.330

3.  Effect of neostigmine on integrity of ileorectal anastomoses.

Authors:  C M Bell; C B Lewis
Journal:  Br Med J       Date:  1968-09-07

4.  Epidural anaesthesia and postoperative colorectal motility--a possible hazard to a colorectal anastomosis.

Authors:  A Carlstedt; S Nordgren; S Fasth; L Appelgren; L Hultén
Journal:  Int J Colorectal Dis       Date:  1989-08       Impact factor: 2.571

  4 in total
  1 in total

Review 1.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.